Weyer J., Rupprecht C.E., Mans J., Viljoen G.J., Nel L.H.
University of Pretoria, Department of Microbiology and Plant Pathology, Pretoria, 0002, South Africa; Centers for Disease Control and Prevention, National Center for Infectious Disease, Division of Viral and Rickettsial Zoonosis, 1600 Clifton Road NE, Atlanta, GA 30333, United States; Agricultural Research Council-Onderstepoort Veterinary Institute, Division of Applied Biotechnology, Onderstepoort, 0110, South Africa
Weyer, J., University of Pretoria, Department of Microbiology and Plant Pathology, Pretoria, 0002, South Africa; Rupprecht, C.E., Centers for Disease Control and Prevention, National Center for Infectious Disease, Division of Viral and Rickettsial Zoonosis, 1600 Clifton Road NE, Atlanta, GA 30333, United States; Mans, J., Agricultural Research Council-Onderstepoort Veterinary Institute, Division of Applied Biotechnology, Onderstepoort, 0110, South Africa; Viljoen, G.J., Agricultural Research Council-Onderstepoort Veterinary Institute, Division of Applied Biotechnology, Onderstepoort, 0110, South Africa; Nel, L.H., University of Pretoria, Department of Microbiology and Plant Pathology, Pretoria, 0002, South Africa
Modified vaccinia virus Ankara (MVA) has become a vaccine vector of choice for recombinant vaccine development. A MVA-based rabies vaccine would be advantageous for use as a vaccine for dogs (and wildlife), particularly if it proves innocuous and efficacious by the oral route. Here, the generation and immunological testing of a recombinant MVA expressing a rabies virus glycoprotein gene is described. In a murine model, higher dosages of recombinant MVA were needed to induce equivocal immune responses as with Vaccinia Copenhagen or Vaccinia Western Reserve recombinants, when administered by a parenteral route. The MVA recombinant was not immunogenic or efficacious when administered per os in naïve mice. The ability of the recombinant MVA to induce anamnestic responses in dogs and raccoons was also investigated. Recombinant MVA boosted humoral immune responses in these animals when administered peripherally, but not when administered orally. © 2007 Elsevier Ltd. All rights reserved.
modified vaccinia virus Ankara vaccine; rabies vaccine; rabies virus glycoprotein; recombinant modified vaccinia virus ankara virus vector; unclassified drug; vaccinia copenhagen virus vaccine; vaccinia copenhagen virus vector; vaccinia vaccine; vaccinia western reserve vaccine; vaccinia western reserve virus vector; virus vector; animal cell; animal experiment; animal model; article; comparative study; controlled study; drug efficacy; female; gene; humoral immunity; immune response; immunogenicity; immunological procedures; mouse; nonhuman; priority journal; rabies; rabies virus glycoprotein gene; Animals; Antibodies, Viral; Antigens, Viral; Cell Line; Chickens; Cricetinae; Dogs; Female; Glycoproteins; Immunologic Memory; Mesocricetus; Mice; Mice, Inbred BALB C; Models, Animal; Neutralization Tests; Rabies; Rabies Vaccines; Rabies virus; Raccoons; Vaccines, Synthetic; Vaccinia virus; Viral Envelope Proteins